27.09.2012 • News

Neurosearch to Sell Huntexil Drug to Israel's Teva

Danish biopharma company Neurosearch said on Thursday it had signed a 149 million Danish crowns ($25.7 million) deal with Israel's Teva Pharmaceutical Industries for the sale of its Huntington's drug Huntexil.

Under the deal, Neurosearch could also receive potential milestone payments with a total value of up to 55 million crowns, it said in a statement.

The agreement was conditional on Neurosearch shareholder approval as well as a number of standard conditions, it said.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.